orlistat in prediabetes
Last reviewed 10/2021
Orlistat in Prediabetes
NICE suggest that a clinician should use clinical judgement on whether to offer orlistat to people with a BMI of 28.0 kg/m2 or more, as part of an overall plan for managing obesity ( take into account the person's risk and the level of weight loss and lifestyle change required to reduce this risk)
Duration:
- review the use of orlistat after 12 weeks
- if the person has not lost at least 5% of their original body weight, use clinical judgement to decide whether to stop the orlistat
- note however, as with adults who have type 2 diabetes, those at high
risk of the condition may lose weight more slowly than average, so less
strict goals may be appropriate
- only use orlistat for more than 12 months (usually for weight maintenance) after discussing the potential benefits, limitations and side effects with the person concerned
Reference: